Skip to main content
SpringerLink
Log in
Book cover

Sustainable Development for the Healthcare Industry pp 1–37Cite as

Sustainable Development for the Health-Care Industry: Setting the Stage

  • 1630 Accesses

Part of the Perspectives on Sustainable Growth book series (POSG)

Abstract

Health has been a topic of paramount importance and an integral part of fighting for one’s subsistence along with an overlapping with the search for food and shelter, and interestingly it has progressively superseded wealth as a topic of interest. Evidence to that is the Google Ngram chart of the number of books addressing health versus wealth as a core topic; one can only notice that since the 1800s, health-focused books have always outnumbered those related to wealth by anywhere between 10 and 20 % up until the 1920s. From the beginning of the twentieth century, the number of books focused on health skyrocketed (with an acceleration since the 1970s) and the lead of health over wealth as a literature topic is now close to fivefold as expressed in total number of books.

Keywords

  • Corporate Responsibility
  • Intellectual Property Right
  • Corporate Sustainability
  • Entire Life Cycle
  • Care Procurement

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, access via your institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Notes

  1. 1.

    https://books.google.com/ngrams/graph?content=health%2C+wealth&year_start=1800&year_end=2000&corpus=15&smoothing=3&share=&direct_url=t1%3B%2Chealth%3B%2Cc0%3B.t1%3B%2Cwealth%3B%2Cc0. Accessed 6 July 2014.

  2. 2.

    http://www.ifpma.org/about-ifpma/welcome.html. Accessed 6 July 2014.

  3. 3.

    IFPMA Facts and Figures 2012.

  4. 4.

    http://www.ifpma.org/fileadmin/content/Publication/2012/IFPMA_CorpBrochureWEBVERSION.pdf. Accessed 6 July 2014.

  5. 5.

    http://www.fda.gov/AboutFDA/WhatWeDo/History/ProductRegulation/SummaryofNDAApprovalsReceipts1938tothepresent/default.htm. Accessed 6 July 2014.

  6. 6.

    Scrip Research and Pharmaprojects 2013 Citeline.

  7. 7.

    http://stats.oecd.org/Index.aspx?DataSetCode=SHA#. Accessed 6 July 2014.

  8. 8.

    Euro Health Consumer Index Report 2009.

  9. 9.

    Analysis of data from WHO, The Commonwealth Fund, Frontier Centre.

  10. 10.

    https://image-store.slidesharecdn.com/561a0856-b834-11e3-a614-22000a9780da-original.jpeg. Accessed 1 June 2014.

  11. 11.

    Economist Intelligence Unit Survey, July 2012.

  12. 12.

    http://mashable.com/2013/12/21/technology-age-comic/. Accessed 1 June 2014.

  13. 13.

    Online searches at PubMed http://www.ncbi.nlm.nih.gov/pubmed. Accessed 1 June 2014.

  14. 14.

    http://www.scripintelligence.com/home/ACC-PREVIEW-What-drug-trials-will-be-hot-in-Washington-DC-350858. Accessed 19 July 2014.

  15. 15.

    http://www.scripintelligence.com/home/Healthcare-2030-facing-up-to-a-pharma-future-346693. Accessed 17 July 2014.

  16. 16.

    http://brainfoodtv.com/personalized-medicine-who-needs-it-and-what-for/#.U8qQ6LHmcSQ. Accessed 15 July 2014.

  17. 17.

    http://www.nytimes.com/2012/11/09/business/sanofi-halves-price-of-drug-after-sloan-kettering-balks-at-paying-it.html?_r=0. Accessed 15 Aug 2014.

  18. 18.

    http://www.cancerletter.com/articles/20130628_2. Accessed 15 Aug 2014.

  19. 19.

    http://www.nytimes.com/2014/08/03/upshot/is-a-1000-pill-really-too-much.html?abt=0002&abg=0. Accessed 15 Aug 2014.

  20. 20.

    http://www.webmd.com/hepatitis/news/20140714/high-cost-hepatitis-c-drug-sovaldi-investigated. Accessed 15 Aug 2014.

  21. 21.

    http://www.techtimes.com/articles/12045/20140805/sovaldi-hepatitis-c-drug-at-84–000-per-treatment-course-sparks-healthcare-concerns.htm. Accessed 15 Aug 2014.

  22. 22.

    EPA to evaluate 134 chemicals for endocrine disruption http://www.environmentalleader.com/2010/11/17/epa-to-evaluate-134-chemicals-for-endocrine-disruption/. Accessed 10 Nov 2013.

  23. 23.

    Pfizer discusses its strategic plant restructuring & energy master plan. http://www.environmentalleader.com/2011/04/11/pfizer-discusses-its-strategic-plant-restructuring-energy-master-plan/. Accessed 10 Nov 2013.

  24. 24.

    Implementing the pharmaceutical industry principles for responsible supply chain management, pharmaceutical supply chain initiative. http://www.pharmaceuticalsupplychain.org/downloads/psci_guidance.pdf.

  25. 25.

    Strategy for UK life sciences-one year on, Project Director: Dr Sarah Garner. http://casmi.org.uk/adaptive-licensing/ (2012). Accessed 23 Mar 2014.

  26. 26.

    http://www.theprostatenet.org/aboutUs.html. Accessed 15 Aug 2014.

  27. 27.

    GlaxoSmithKline aims to collect 100,000 inhalers. http://www.environmentalleader.com/2012/10/25/glaxosmithkline-aims-to-collect-100000-inhalers/. Accessed 10 Nov 2013.

  28. 28.

    Johnson & Johnson expands green product range. http://www.environmentalleader.com/2012/03/02/johnson-johnson-expands-green-product-range/. Accessed 10 Nov 2013.

  29. 29.

    Working toward transformational health partnerships in low and middle income countries, BSR; 2012.

  30. 30.

    Gearing Up: From corporate responsibility to good governance and scalable solutions, http://www.sustainability.com/library/gearing-up?path=gearing-up#.UTYBhYlespo. Accessed 23 Mar 2014.

  31. 31.

    Issue Brief: Progressive alliances, scaling up corporate responsibility to address global challenges http://www.sustainability.com/library/issue-brief-progressive-alliances#.UTYAn4lespo. Accessed 23 Mar 2014.

  32. 32.

    GlaxoSmithKline sets carbon neutrality goal for 2050 http://www.environmentalleader.com/2011/03/30/glaxosmithkline-sets-carbon-neutrality-goal-for-2050/. Accessed 10 Nov 2013.

  33. 33.

    Energy-efficient measures saves Pfizer $ 2.6M in 2009 http://www.environmentalleader.com/2010/10/07/energy-efficient-measures-saves-pfizer-2-6m-in-2009/. Accessed 10 Nov 2013.

  34. 34.

    Johnson & Johnson COMPLETES LARGEST SOLAR PANEL ARRay in NJ http://www.environmentalleader.com/2010/09/22/johnson-johnson-completes-largest-solar-panel-array-in-nj/. Accessed 10 Nov 2014.

  35. 35.

    Novo Nordisk Cuts CO2 Emissions by 32 %, Water Use by 20 % http://www.environmentalleader.com/2010/02/08/novo-nordisk-cuts-co2-emissions-by-32-water-use-by-20/. Accessed 10 Nov 2013.

  36. 36.

    Lilly meets energy-efficiency goals ahead of schedule. http://www.environmentalleader.com/2009/10/23/lilly-meets-energy-efficiency-goals-ahead-of-schedule/. Accessed 10 Nov 2013

  37. 37.

    Pfizer exceeds emissions reduction goals, misses clean energy target. http://www.environmentalleader.com/2009/10/07/pfizer-exceeds-emissions-reduction-goals-misses-clean-energy-target/. Accessed 10 Nov 2013.

  38. 38.

    Bristol-Myers Squibb, Sanofi-Aventis tops pharmaceutical sustainability report. http://www.environmentalleader.com/2009/12/15/bristol-myers-squibb-sanofi-aventis-tops-pharmaceutical-sustainability-report/?graph=full&id=1. Accessed 10 Nov 2013

  39. 39.

    https://www.claremontmckenna.edu/roberts-environmental-center/wp-content/uploads/2014/02/Pharmaceuticals2012.pdf. Accessed 15 Aug 2014.

References

  • Barker R. A flexible blueprint for the future of drug development. Lancet 2010;375:357–9.

    CrossRef  Google Scholar 

  • Barker R, Garner S. Adaptive drug development and licensing. Regulatory Rapporteur 2012;9, 10:13–5.

    Google Scholar 

  • Baumol WJ. The cost disease, why computers get cheaper and health care doesn’t. Yale University Press, USA; 25 Sept 2012. ISBN: 9780300179286.

    Google Scholar 

  • Daughton CG. Chemicals from the practice of healthcare: challenges and unknowns posed by residues in the environment. Environ Toxicol Chem. 2009;28(12):2490–4. http://onlinelibrary.wiley.com/doi/10.1897/09-138.1/abstract. Accessed 3 Aug 2014.

    CrossRef  Google Scholar 

  • Daughton CG, et al. Environmental footprint of pharmaceuticals: the significance of factors beyond direct excretion to sewers. Environ Toxicol Chem. 2009;28(12):2495–521. http://onlinelibrary.wiley.com/doi/10.1897/08-382.1/full. Accessed 3 Aug 2014.

    CrossRef  Google Scholar 

  • Daughton CG, et al. Lower-dose prescribing: minimizing “side effects” of pharmaceuticals on society and the environment. Sci Total Environ. 2013;443:324–37.

    CrossRef  Google Scholar 

  • Davis I. The biggest contract. The Economist; 26 May 2005. http://www.economist.com/node/4008642. Accessed 10 Nov 2013.

  • Dunn PJ, Wells A, Williams MT, editors. Green chemistry in the pharmaceutical industry. 2010 (ISBN: 978–3-527–32418-7).

    Google Scholar 

  • Eichler HG, et al. Adaptive licensing: taking the next step in the evolution of drug licensing. Clin Pharmacol Ther. 2012;91(3):426–37. doi:10.1038/clpt.2011.345 (Epub 15 Feb 2012).

    CrossRef  Google Scholar 

  • Greider W. The soul of capitalism—opening path to a moral economy. Simon & Schuster, New York; 2003.

    Google Scholar 

  • IFPMA. Developing world health partnerships directory. IFPMA Report; 2010.

    Google Scholar 

  • IFPMA. Technology transfer: a collaborative approach to improve global health. IFPMA Report; 2011.

    Google Scholar 

  • Johnson & Johnson. 54 % of hospitals say green attributes important in purchasing. Report. http://www.environmentalleader.com/2012/09/26/johnson-johnson-report-54-of-hospitals-say-green-attributes-important-in-purchasing/ (2012). Accessed 10 Nov 2013.

  • Juniper T. What has nature ever done for us? Profile Books, London, UK; 2013 (ISBN 978–1-84668–560-6).

    Google Scholar 

  • Kümmerer K. Sustainable from the very beginning: rational design of molecules by life cycle engineering as an important approach for green pharmacy and green chemistry. Green Chem. 2007;9:899–907. doi:10.1039/B618298B (Received 14 Dec 2006, Accepted 15 Mar 2007, First published on the web 05 Apr 2007).

    CrossRef  Google Scholar 

  • Kümmerer K. Antibiotics in the aquatic environment—a review—Part I. Chemosphere 2009a;75(4):417–34.

    CrossRef  Google Scholar 

  • Kümmerer K. The presence of pharmaceuticals in the environment due to human use—present knowledge and future challenges. J Environ Manag. 2009b;90(8):2354–66.

    CrossRef  Google Scholar 

  • Kümmerer K, Hempel M, editors. Green and sustainable pharmacy. 1st ed. Vol. XVII, Springer, New York, USA, p. 313 40 illus. 2010. ISBN 978-3-642-05199-9.

    Google Scholar 

  • Leadbetter C. We think. Profile Books Ltd, London, UK (ISBN 978-1861978370); 2009.

    Google Scholar 

  • Mihelcic JR, et al. Integrating developed and developing, world knowledge into global discussions and strategies for sustainability. 1. Science and technology. Environ Sci Technol. 2007; 41(10):3415–21.

    Google Scholar 

  • Mistra Pharma: A healthy future—pharmaceuticals in a sustainable society. 2009 (Published in collaboration between Apoteket AB, MistraPharma and Stockholm, Sweden County Council).

    Google Scholar 

  • Pan American Sanitary Bureau. Biodiversity, biotechnology, and sustainable development in health and agriculture. 1996 (ISBN: 92 75 11560 5)

    Google Scholar 

  • Paul SM, et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov. 2010;9:203–14.

    Google Scholar 

  • Peterson K, et al. Competing by saving lives: how pharmaceutical and medical device companies create shared value in global health, 2012—report http://www.fsg.org/tabid/191/ArticleId/557/Default.aspx?srpush=true. Accessed 23 Mar 2014.

  • Pharma Futures 1. The pharmaceutical sector: a long-term value outlook. 2004. http://pharmafutures.org/pharmafutures-1/a-long-term-value-outlook/. Accessed 23 Mar 2014.

  • Pharma Futures 2. Prescription for long-term value. 19 Jun 2007—Report http://www.sustainability.com/library/pharma-futures-2#.UTYG04lespo. Accessed 23 Mar 2014.

  • Pharma Futures 3. Emerging opportunities-23 Feb 2009—Report http://pharmafutures.org/pharmafutures-3/emerging-opportunities/. Accessed 23 Mar 2014.

  • Pharma Futures 4. Shared value, 2011—report. http://pharmafutures.org/pharmafutures-4/sharedvalue/. Accessed 23 Mar 2014.

  • Pharma Futures 5. Innovation and productivity in health systems, 2012—report. http://pharmafutures.org/pharmafutures-5/innovation-in-health-systems/. Accessed 23 Mar 2014.

  • Porter M, Kramer M. Creating shared value. Harv Bus Rev. 2011;89(1–2):62–77.

    Google Scholar 

  • Rücker C, et al. Modeling and predicting aquatic aerobic biodegradation—a review from a user’s perspective. Green Chem. 2012;14:875–87. doi:10.1039/C2GC16267A.

    CrossRef  Google Scholar 

  • Wennmalm A, et al. Drug design should involve consideration of environmental risk and hazard. Lett Drug Des Discov. 2008;5(4):232–5.

    CrossRef  Google Scholar 

  • Wennmalm A, et al. The vision—sustainable pharmaceutical management in a sustainable society. MistraPharma, April 2010, p. 130.

    Google Scholar 

  • World Economic Forum. Sustainable health systems: visions, strategies, critical uncertainties and scenarios. January 2013.

    Google Scholar 

  • World Health Summit 2012. Research for health and sustainable development, M8 Alliance; 2012.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. AJ Biologics, Kuala Lumpur, Malaysia

    Pierre A. Morgon

  2. Theradiag, Croissy-Beaubourg, France

    Pierre A. Morgon

  3. Eurocine Vaccines, Solna, Sweden

    Pierre A. Morgon

Authors
  1. Pierre A. Morgon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pierre A. Morgon .

Editor information

Editors and Affiliations

  1. MRGN Advisors, Lausanne, Switzerland

    Pierre A. Morgon

Rights and permissions

Reprints and Permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Morgon, P. (2015). Sustainable Development for the Health-Care Industry: Setting the Stage. In: Morgon, P. (eds) Sustainable Development for the Healthcare Industry. Perspectives on Sustainable Growth. Springer, Cham. https://doi.org/10.1007/978-3-319-12526-8_1

Download citation

search

Navigation